Servier and Galapagos have entered into a multiyear alliance that is potentially worth more than €260 M (US$348 M) to discover and develop new small molecule cancer therapies. Galapagos will be responsible for the discovery and preclinical development of drug candidates against a number of targets contributed by both companies. After preclinical studies have been completed, Servier will have an exclusive option to license each programme, except in the US where Galapagos retains exclusive rights. The two companies have a similar partnership for osteoarthritis.